• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2021年12月至2022年6月期间,对感染新冠病毒奥密克戎变异株出现症状后的抗体反应。

Antibody response to symptomatic infection with SARS-CoV-2 Omicron variant viruses, December 2021-June 2022.

作者信息

Sandford Ryan, Yadav Ruchi, Noble Emma K, Sumner Kelsey, Joshi Devyani, Tartof Sara Y, Wernli Karen J, Martin Emily T, Gaglani Manjusha, Zimmerman Richard K, Talbot H Keipp, Grijalva Carlos G, Belongia Edward A, Carlson Christina, Coughlin Melissa, Flannery Brendan, Pearce Brad, Rogier Eric

机构信息

Centers for Disease Control and Prevention, Atlanta, GA, USA.

Oak Ridge Institute for Science and Education, Oak Ridge, TN, USA.

出版信息

medRxiv. 2023 Nov 18:2023.11.17.23298700. doi: 10.1101/2023.11.17.23298700.

DOI:10.1101/2023.11.17.23298700
PMID:38014151
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10680903/
Abstract

To describe humoral immune responses to symptomatic SARS-CoV-2 infection, we assessed immunoglobulin G binding antibody levels using a commercial multiplex bead assay against SARS-CoV-2 ancestral spike protein receptor binding domain (RBD) and nucleocapsid protein (N). We measured binding antibody units per mL (BAU/mL) during acute illness within 5 days of illness onset and during convalescence in 105 ambulatory patients with laboratory-confirmed SARS-CoV-2 infection with Omicron variant viruses. Comparing acute- to convalescent phase antibody concentrations, geometric mean anti-N antibody concentrations increased 47-fold from 5.5 to 259 BAU/mL. Anti-RBD antibody concentrations increased 2.5-fold from 1258 to 3189 BAU/mL.

摘要

为了描述对有症状的SARS-CoV-2感染的体液免疫反应,我们使用针对SARS-CoV-2原始刺突蛋白受体结合域(RBD)和核衣壳蛋白(N)的商业多重珠分析来评估免疫球蛋白G结合抗体水平。我们在105例实验室确诊感染奥密克戎变异株病毒的门诊SARS-CoV-2感染患者的急性疾病期(发病后5天内)和恢复期测量了每毫升的结合抗体单位(BAU/mL)。比较急性期和恢复期的抗体浓度,抗N抗体的几何平均浓度从5.5 BAU/mL增加到259 BAU/mL,增长了47倍。抗RBD抗体浓度从1258 BAU/mL增加到3189 BAU/mL,增长了2.5倍。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b19/10680903/87b3515e3f4c/nihpp-2023.11.17.23298700v1-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b19/10680903/87b3515e3f4c/nihpp-2023.11.17.23298700v1-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b19/10680903/87b3515e3f4c/nihpp-2023.11.17.23298700v1-f0001.jpg

相似文献

1
Antibody response to symptomatic infection with SARS-CoV-2 Omicron variant viruses, December 2021-June 2022.2021年12月至2022年6月期间,对感染新冠病毒奥密克戎变异株出现症状后的抗体反应。
medRxiv. 2023 Nov 18:2023.11.17.23298700. doi: 10.1101/2023.11.17.23298700.
2
Antibody Response to Symptomatic Infection With SARS-CoV-2 Omicron Variant Viruses, December 2021-June 2022.2021 年 12 月至 2022 年 6 月期间对 SARS-CoV-2 奥密克戎变异病毒感染的抗体反应。
Influenza Other Respir Viruses. 2024 Jul;18(7):e13339. doi: 10.1111/irv.13339.
3
Trends of humoral immune responses to heterologous antigenic exposure due to vaccination & omicron SARS-CoV-2 infection: Implications for boosting.由于疫苗接种和奥密克戎 SARS-CoV-2 感染导致的针对异源抗原暴露的体液免疫反应趋势:对增强作用的影响。
Indian J Med Res. 2023 Jun;157(6):509-518. doi: 10.4103/ijmr.ijmr_2521_22.
4
Anti-SARS-CoV-2 Antibody Levels Associated With COVID-19 Protection in Outpatients Tested for SARS-CoV-2, US Flu Vaccine Effectiveness Network, October 2021-June 2022.与 COVID-19 保护相关的抗 SARS-CoV-2 抗体水平,在 2021 年 10 月至 2022 年 6 月期间,美国流感疫苗有效性网络对检测 SARS-CoV-2 的门诊患者进行检测。
J Infect Dis. 2024 Jul 25;230(1):45-54. doi: 10.1093/infdis/jiae090.
5
Anti-SARS-CoV-2 Antibody Levels Associated with COVID-19 Protection in Outpatients Tested for SARS-CoV-2, US Flu VE Network, October 2021-June 2022.2021年10月至2022年6月,美国流感疫苗效力网络中接受新冠病毒检测的门诊患者体内抗新冠病毒2抗体水平与新冠病毒疾病防护的相关性
medRxiv. 2023 Sep 23:2023.09.21.23295919. doi: 10.1101/2023.09.21.23295919.
6
Trajectory of Humoral Responses to Two Doses of ChAdOx1 nCoV-19 Vaccination in Patients Receiving Maintenance Hemodialysis.接受维持性血液透析的患者对两剂ChAdOx1 nCoV-19疫苗接种的体液免疫反应轨迹
Microbiol Spectr. 2023 Feb 21;11(2):e0344522. doi: 10.1128/spectrum.03445-22.
7
Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.真实世界中衰弱老年人接受延长间隔和异源 COVID-19 mRNA 疫苗接种后的血清学反应(UNCoVER):一项前瞻性观察队列研究的中期报告。
Lancet Healthy Longev. 2022 Mar;3(3):e166-e175. doi: 10.1016/S2666-7568(22)00012-5. Epub 2022 Feb 23.
8
Analysis of Serological Biomarkers of SARS-CoV-2 Infection in Convalescent Samples From Severe, Moderate and Mild COVID-19 Cases.严重、中度和轻度 COVID-19 病例恢复期样本中 SARS-CoV-2 感染的血清学生物标志物分析。
Front Immunol. 2021 Nov 19;12:748291. doi: 10.3389/fimmu.2021.748291. eCollection 2021.
9
Determinants of protection against SARS-CoV-2 Omicron BA.1 and Delta infections in fully vaccinated outpatients.完全接种疫苗的门诊患者中针对 SARS-CoV-2 奥密克戎 BA.1 和德尔塔感染的保护因素。
J Med Virol. 2023 Aug;95(8):e28984. doi: 10.1002/jmv.28984.
10
Detection of SARS-CoV-2 antibodies after confirmed Omicron BA.1 and presumed BA.4/5 infections using Abbott ARCHITECT and Panbio assays.使用雅培ARCHITECT和Panbio检测方法在确诊感染奥密克戎BA.1以及推测感染BA.4/5后检测新型冠状病毒2型抗体。
IJID Reg. 2023 Jun;7:277-280. doi: 10.1016/j.ijregi.2023.04.014. Epub 2023 May 12.

本文引用的文献

1
Anti-SARS-CoV-2 Antibody Levels Associated With COVID-19 Protection in Outpatients Tested for SARS-CoV-2, US Flu Vaccine Effectiveness Network, October 2021-June 2022.与 COVID-19 保护相关的抗 SARS-CoV-2 抗体水平,在 2021 年 10 月至 2022 年 6 月期间,美国流感疫苗有效性网络对检测 SARS-CoV-2 的门诊患者进行检测。
J Infect Dis. 2024 Jul 25;230(1):45-54. doi: 10.1093/infdis/jiae090.
2
Differential Severe Acute Respiratory Syndrome Coronavirus 2-Specific Humoral Response in Inactivated Virus-Vaccinated, Convalescent, and Breakthrough-Infected Subjects.灭活病毒疫苗接种、康复和突破性感染受试者中 SARS-CoV-2 特异性体液反应的差异。
J Infect Dis. 2023 Oct 3;228(7):857-867. doi: 10.1093/infdis/jiad320.
3
Prior SARS-CoV-2 infection and COVID-19 vaccine effectiveness against outpatient illness during widespread circulation of SARS-CoV-2 Omicron variant, US Flu VE network.
在 SARS-CoV-2 奥密克戎变异株广泛传播期间,既往 SARS-CoV-2 感染和 COVID-19 疫苗对门诊疾病的有效性,美国流感疫苗效果监测网络。
Influenza Other Respir Viruses. 2023 May;17(5):e13143. doi: 10.1111/irv.13143.
4
Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial.比较 COVE mRNA-1273 疫苗疗效试验中针对 COVID-19 的抗体检测作为保护相关性。
Sci Transl Med. 2023 Apr 19;15(692):eade9078. doi: 10.1126/scitranslmed.ade9078.
5
Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine.AZD1222(ChAdOx1 nCoV-19)疫苗3期试验的免疫相关分析。
NPJ Vaccines. 2023 Mar 11;8(1):36. doi: 10.1038/s41541-023-00630-0.
6
Kinetics of the Antibody Response to Symptomatic SARS-CoV-2 Infection in Vaccinated and Unvaccinated Individuals in the Blinded Phase of the mRNA-1273 COVID-19 Vaccine Efficacy Trial.mRNA-1273新冠疫苗有效性试验盲法阶段中接种和未接种个体对有症状的SARS-CoV-2感染的抗体反应动力学
Open Forum Infect Dis. 2023 Feb 13;10(3):ofad069. doi: 10.1093/ofid/ofad069. eCollection 2023 Mar.
7
Immunity of Heterologously and Homologously Boosted or Convalescent Individuals Against Omicron BA.1, BA.2, and BA.4/5 Variants.异源和同源加强或康复个体对奥密克戎 BA.1、BA.2 和 BA.4/5 变异株的免疫。
J Infect Dis. 2023 Jul 14;228(2):160-168. doi: 10.1093/infdis/jiad057.
8
Predicting the efficacy of variant-modified COVID-19 vaccine boosters.预测变异株改良 COVID-19 疫苗加强针的效力。
Nat Med. 2023 Mar;29(3):574-578. doi: 10.1038/s41591-023-02228-4. Epub 2023 Mar 2.
9
Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial.预防 19 型 COVID-19 疫苗疗效临床试验的免疫相关性分析。
Nat Commun. 2023 Jan 19;14(1):331. doi: 10.1038/s41467-022-35768-3.
10
Dried blood spots are a valid alternative to venipuncture for COVID-19 antibody testing.干血斑是一种替代静脉采血的有效方法,可用于 COVID-19 抗体检测。
J Immunol Methods. 2023 Feb;513:113420. doi: 10.1016/j.jim.2022.113420. Epub 2022 Dec 31.